Perspective Therapeutics (NYSEAMERICAN:CATX) Hits New 12-Month High at $1.62

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX)’s stock price reached a new 52-week high during trading on Tuesday . The company traded as high as 1.62 and last traded at 1.60, with a volume of 1449231 shares traded. The stock had previously closed at 1.53.

Analyst Ratings Changes

A number of equities analysts recently commented on CATX shares. B. Riley increased their price objective on Perspective Therapeutics from $1.20 to $1.70 and gave the stock a “buy” rating in a report on Tuesday, April 9th. Oppenheimer restated an “outperform” rating and issued a $1.50 price objective (up previously from $1.20) on shares of Perspective Therapeutics in a report on Monday, April 1st.

Perspective Therapeutics Trading Up 8.8 %

The stock has a market capitalization of $977.22 million, a PE ratio of -16.85 and a beta of 1.56. The company has a quick ratio of 1.07, a current ratio of 1.07 and a debt-to-equity ratio of 0.02.

Insider Activity

In other Perspective Therapeutics news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of Perspective Therapeutics stock in a transaction dated Wednesday, March 6th. The stock was bought at an average cost of 0.95 per share, with a total value of 57,409,487.05. Following the completion of the transaction, the insider now owns 116,773,394 shares of the company’s stock, valued at 110,934,724.30. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of Perspective Therapeutics stock in a transaction that occurred on Wednesday, March 6th. The stock was purchased at an average cost of 0.95 per share, with a total value of 57,409,487.05. Following the completion of the transaction, the insider now directly owns 116,773,394 shares in the company, valued at 110,934,724.30. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Markus Puhlmann bought 280,000 shares of Perspective Therapeutics stock in a transaction that occurred on Wednesday, January 24th. The stock was purchased at an average cost of 0.50 per share, with a total value of 140,000.00. Following the completion of the transaction, the insider now owns 1,375,425 shares of the company’s stock, valued at 687,712.50. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 60,758,439 shares of company stock valued at $57,576,503. 5.72% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Taylor & Morgan Wealth Management LLC boosted its holdings in Perspective Therapeutics by 8.7% in the fourth quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company’s stock valued at $251,000 after acquiring an additional 50,000 shares during the last quarter. Bank of New York Mellon Corp bought a new position in Perspective Therapeutics in the third quarter valued at about $42,000. HighTower Advisors LLC bought a new position in Perspective Therapeutics in the third quarter valued at about $314,000. Finally, Perkins Capital Management Inc. bought a new position in Perspective Therapeutics in the third quarter valued at about $731,000. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.